INTRAVITREOUS INJECTION OF BEVACIZUMAB, TISSUE PLASMINOGEN ACTIVATOR, AND GAS IN THE TREATMENT OF SUBMACULAR HEMORRHAGE IN AGE-RELATED MACULAR DEGENERATION

To investigate the benefit of adding bevacizumab to intravitreal recombinant tissue plasminogen activator (rTPA) and gas as initial therapy in subretinal hemorrhage and choroidal neovascularization because of age-related macular degeneration.Thirty-eight consecutive patients with recent (1-31 days) subretinal hemorrhage who were treated with intravitreal rTPA and gas (26 patients) or with intravitreal bevacizumab, rTPA, and gas (12 patients)...